This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 24, 2012 9:30 a.m. ET
Albert Fleury – Director Investor Relations North America
Peer Schatz – Chief Executive Officer
Roland Sackers – Chief Financial Officer
John Gilardi – Vice President, Corporate Communications and Investor Relations
Daniel Wendorff - Commerzbank
Tycho Peterson - JP Morgan
Quintin Lai - Baird
Martin Wales - UBS
Zarak Khurshid - Wedbusch
Travis - Macquarie
Bill Bonello - RBC Capital Markets
Brian Weinstein - William Blair & Company
Peter Lawson - Mizuho Securities
Dan Leonard - Leerink Swann
Ladies and gentlemen, thank you for standing by. Welcome to QIAGEN N.V. investor and analyst conference call on the Q1 results 2012. (Operator instructions) I would not like to turn the conference over to Albert Fleury, Director Investor Relations and Corporate Finance NA. Please go ahead, sir.
Thank you. Good afternoon and good morning to you in the U.S. and welcome to the QIAGEN conference call to discuss our latest quarterly results. Joining me on the call this morning are Peer Schatz, Chief Executive Officer, Roland Sackers, Chief Financial Officer, and John Gilardi, Vice President, Corporate Communications and Investor Relations. A copy of this announcement and the presentation for this conference can be downloaded from the Investor Relation’s section of our home page at www.qiagen.com.
Before I turn the call over to Peer, please keep in mind that the following discussion and responses to your questions reflect management’s view as of today, April 26, 2012. As we share information to help you better understand our business, we will make statements and provide responses that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. These involve certain risks and uncertainties that could cause QIAGEN’s actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For a complete description of the risks and uncertainties, please refer to our Form 20-F filed with the U.S. Securities and Exchange Commission.